NCT07417189 2026-03-11
A Phase I/II Study of ABSK141 in Patients With Advanced Solid Tumors ( ABSK141-101 )
Abbisko Therapeutics Co, Ltd
Phase 1/2 Recruiting
Abbisko Therapeutics Co, Ltd
Hutchmed
Novo Nordisk A/S
Grit Biotechnology
Shenzhen Celconta Life Science Co., Ltd.